Related Experiment Video
Updated: May 12, 2026
08:52
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
Influenza vaccines: time for a rethink
1Johns Hopkins University School of Medicine, 1620 McElderry St, Reed Hall W, Room 201-C, Baltimore,MD 21205, USA. pnd@jhu.edu
JAMA Internal Medicine
|April 5, 2013
Summary
Annual influenza vaccines may not effectively prevent serious illness, challenging public health assumptions. The article questions vaccine benefits and highlights potential harms, advocating for risk-benefit discussions.
Area of Science:
- Public Health
- Vaccinology
- Epidemiology
Background:
- Influenza is widely considered a significant public health threat.
- Annual vaccination is promoted as a safe and effective preventative measure.
- Current policies assume vaccines significantly reduce severe influenza complications.
Purpose of the Study:
- To critically evaluate the evidence supporting the effectiveness of annual influenza vaccines.
- To examine the conflation of influenza with "flu" and its impact on public perception.
- To discuss potential harms associated with influenza vaccines and inform decision-making.
Main Methods:
- Review of existing scientific literature and policy statements regarding influenza vaccines.
- Analysis of the distinction between influenza and the broader syndrome of "flu".
- Examination of reported adverse events and potential risks of influenza vaccination.
Main Results:
- Limited evidence suggests influenza vaccines effectively reduce serious influenza complications.
- Promotional materials often inaccurately equate "influenza" with "flu," a syndrome with multiple causes.
- Documented instances of unexpected and serious adverse effects from influenza vaccines exist.
Conclusions:
- Current assumptions about the benefits of annual influenza vaccination require re-evaluation.
- Misinformation regarding influenza and "flu" leads to unrealistic expectations of vaccine efficacy.
- Informed decisions about influenza vaccination necessitate a comprehensive discussion of both risks and benefits.
Related Concept Videos
01:51Vaccinations
Overview
01:27Influenza
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
00:57Viral Recombination
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).